Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic facts about biosimilars.

Michał Nowicki1

  • 1Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Łódź, Poland. nefro@wp.pl

Kidney & Blood Pressure Research
|July 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgA-Associated Vasculitis Presenting With Acute Abdominal Syndrome in an Older Patient.

The American journal of case reports·2026
Same author

Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome.

Nutrients·2026
Same author

Long-term toxicity of polydopamine nanoparticles: Organ-specific biological effects and cumulative histopathological changes.

Chemico-biological interactions·2026
Same author

Correction to "Mitochondria-Targeted HA-Coated Nanosystem for ROS/CO Generation and Metabolic Reprogramming to Enhance Tumoricidal Macrophage Polarization".

ACS applied materials & interfaces·2026
Same author

High prevalence of silent aneurysms and fibromuscular dysplasia in spontaneous coronary artery dissection survivors: analysis of the SCAD-POL Registry.

Polish archives of internal medicine·2026
Same author

Hypercalcemia associated with kidney disease: it is not always what you think-a case report.

Journal of medical case reports·2026
Same journal

SIRT6 attenuates angiotensin II-induced podocyte cholesterol accumulation and injury via negative modulation of SREBP2.

Kidney & blood pressure research·2026
Same journal

Epidemiology and multimorbidity in hemodialysis patients at a tertiary care center in northern Mexico: implications for hospital-based adverse outcomes.

Kidney & blood pressure research·2026
Same journal

The inflammatory milieu exacerbates Anemia of CKD:  From the gut-kidney axis to bone marrow hematopoiesis inhibition.

Kidney & blood pressure research·2026
Same journal

Cystine-binding medication is poorly accessible for the treatment of cystinuria.

Kidney & blood pressure research·2026
Same journal

Infective endocarditis-associated glomerulonephritis caused by Streptococcus cristatus: A Case Report.

Kidney & blood pressure research·2026
Same journal

Simplified Subjective Global Assessment at Hemodialysis Initiation and Its Association with 2-Year Mortality and Hospitalization.

Kidney & blood pressure research·2026
See all related articles

Biosimilars, or follow-on biologics, are copies of original biotechnological medicines. While expected to lower healthcare costs, their long-term safety and regulatory aspects require careful physician discussion.

Area of Science:

  • Pharmacology
  • Biotechnology
  • Drug Development

Background:

  • Biotechnological drugs are increasingly vital in pharmacotherapy, projected to dominate the pharmaceutical market.
  • Patent expirations drive the development of biosimilars (follow-on biologics) to replicate original biotechnological medicines.
  • Limited experience and long-term safety data, including immunogenicity, exist for biosimilars.

Purpose of the Study:

  • To discuss critical issues surrounding biosimilars for physicians.
  • To differentiate biosimilars from traditional generics.
  • To address regulatory needs and potential safety concerns.

Main Methods:

  • Review of current literature and regulatory landscape for biosimilars.
  • Analysis of differences between biosimilars and chemical generics.

Related Experiment Videos

  • Discussion of pharmacovigilance, naming, labeling, and substitution policies.

    • Main Results:

    • The European Union has approved initial biosimilars, with more expected.
    • Significant differences exist between biosimilars and generics.
    • Long-term safety and immunogenicity data for biosimilars are currently limited.

    Conclusions:

    • Biosimilars offer potential cost reductions but necessitate careful consideration of safety, regulation, and physician education.
    • Appropriate regulatory frameworks and clear guidelines are crucial for biosimilar integration.
    • Further research on long-term safety, immunogenicity, and pharmacovigilance is essential.